StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026Score 7/30346% above fair value
$359.41−16.69 (-4.44%)

Close on Oct 30, 2026Market cap $17.16BP/E –Yield –

Earnings

Charles River Laboratories International's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 4, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
$1.00B
-3.1% on a year earlier
diluted earnings per share on a non-GAAP basis, Q2 FY2026
$3.02
$3.12 a year earlier
Latest guidance
Raised
Aug 5, 2026 · 4 items

Quarterly results

Revenue and earnings per share from each of Charles River Laboratories International's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q3 FY2026ended Sep 27, 2026Nov 4, 2026Expected–––––
Q2 FY2026ended Jun 27, 2026Aug 5, 2026before the open$1.00B-3.1%-$0.03$3.02Release
Q1 FY2026ended Mar 28, 2026May 7, 2026before the open$995.80M+1.2%-$0.30–Release
Q4 FY2025ended Dec 27, 2025Jan 13, 2026before the open––––Filing
Q3 FY2025ended Sep 27, 2025Nov 5, 2025before the open$1.00B-1.0%$1.10$2.43Release
Q2 FY2025ended Jun 28, 2025Aug 6, 2025before the open$1.03B+0.2%$1.06$3.12Release
Q1 FY2025ended Mar 29, 2025May 7, 2025before the open$984.20M–$0.50$2.34Release
Q4 FY2024ended Dec 28, 2024Feb 19, 2025before the open$1.00B-0.7%-$4.22$2.66Release
Q3 FY2024ended Sep 28, 2024Nov 6, 2024before the open$1.01B-1.9%$1.33$2.59Release
Q2 FY2024ended Jun 29, 2024Aug 7, 2024before the open$1.03B-2.8%$1.74$2.80Release
Q1 FY2024ended Mar 30, 2024May 9, 2024before the open––––Filing
Q4 FY2023ended Dec 30, 2023Feb 14, 2024before the open$1.01B-8.2%$3.62$2.46Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Charles River Laboratories International's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Revenue growth/(decrease), organicnon-GAAPFY20260% – +1%-1.5% – -0.5%RaisedAug 5, 2026
Revenue growth/(decrease), reportedGAAPFY2026-3.5% – -2.5%-5.5% – -4%RaisedAug 5, 2026
GAAP EPS estimateGAAPFY2026$3.05 – $3.35$5.35 – $5.85LoweredAug 5, 2026
Non-GAAP EPS estimatenon-GAAPFY2026$11.15 – $11.45$10.80 – $11.30RaisedAug 5, 2026

Guidance history

Every forecast Charles River Laboratories International put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 5, 2026Non-GAAP EPS estimateFY2026$11.15 – $11.45Raised
Aug 5, 2026GAAP EPS estimateFY2026$3.05 – $3.35Lowered
Aug 5, 2026Revenue growth/(decrease), reportedFY2026-3.5% – -2.5%Raised
Aug 5, 2026Revenue growth/(decrease), organicFY20260% – +1%Raised
May 7, 2026Non-GAAP EPS estimateFY2026$10.80 – $11.30New
May 7, 2026GAAP EPS estimateFY2026$5.35 – $5.85New
May 7, 2026Revenue growth/(decrease), reportedFY2026-5.5% – -4%New
May 7, 2026Revenue growth/(decrease), organic (2)FY2026-1.5% – -0.5%New
Nov 5, 2025Non-GAAP EPS estimateFY2025$10.10 – $10.30Raised
Nov 5, 2025GAAP EPS estimateFY2025$4.15 – $4.35Lowered
Nov 5, 2025Revenue growth/(decrease), reportedFY2025-1.5% – -0.5%Raised
Nov 5, 2025Revenue growth/(decrease), organicFY2025-2.5% – -1.5%Narrowed
Aug 6, 2025Non-GAAP EPS estimateFY2025$9.90 – $10.30New
Aug 6, 2025GAAP EPS estimateFY2025$4.25 – $4.65New
Aug 6, 2025Revenue growth/(decrease), reportedFY2025-2.5% – -0.5%New
Aug 6, 2025Revenue growth/(decrease), organicFY2025-3% – -1%New
May 7, 2025Non-GAAP EPS estimateFY2025$9.30 – $9.80Raised
May 7, 2025GAAP EPS estimateFY2025$4.35 – $4.85Raised
May 7, 2025Revenue growth/(decrease), reportedFY2025-5.5% – -3.5%Raised
May 7, 2025Revenue growth/(decrease), organic (1)FY2025-4.5% – -2.5%Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Charles River Laboratories International filed with the SEC as exhibits to Form 8-K or 6-K

  1. 8-K exhibit EX-99.1
    Update
  2. Charles River Laboratories Announces Second-Quarter 2026 Results
    Results
  3. of $(0.30), and Non-GAAP Earnings per Share of $2.06 –
    Results
  4. CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER
    Results
  5. and Non-GAAP Earnings per Share of $2.43 –
    Results
  6. Michael G. Knell, Corporate Senior Vice President & Chief Accounting Officer,
    Update
  7. and Non-GAAP Earnings per Share of $3.12 –
    Results
  8. Charles River Laboratories Announces Governance
    Update
  9. and Non-GAAP Earnings per Share of $2.34 –
    Results
  10. CHARLES RIVER LABORATORIES ANNOUNCES FOURTH-QUARTER
    Results
  11. and Non-GAAP Earnings per Share of $2.59 –
    Results
  12. and Non-GAAP Earnings per Share of $2.80 –
    Results
  13. Charles River Laboratories Announces Fourth Quarter and Full-Year 2023 Results and Provides 2024 Guidance
    Results
  14. Charles River Laboratories Announces Third-Quarter 2023 Results
    Results
  15. Charles River Laboratories Announces Second-Quarter 2023 Results
    Results